Xiaobo Li
Tianjin Medical University
14 Papers
44 Citations
Xiaobo Li is an academic researcher from Tianjin Medical University. The author has contributed to research in topics: Cancer & Metastasis. The author has an hindex of 8, co-authored 13 publications. Previous affiliations of Xiaobo Li include Emory University & Case Western Reserve University.
Chat about Author
Papers
MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling.
Ke Xu,Guo Chen,Xiaobo Li,Xiaoqin Wu,Zhijie Chang,Jianhua Xu,Yu Zhu,Peihao Yin,Xin Liang,Lei Dong,Lei Dong +10 more
TL;DR: This study provides novel insights into the tumor progression associated with MFN2 deficiency and suggests that the importance of mTORC2 inhibitor in the treatment ofMFN2 downregulated cancer patients is suggested.
Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice
TL;DR: Clarifying the CXCR4/CXCL12 axis and role of AMD3100 will help remove malignant cells from the bone marrow niche, rendering them more accessible to targeted therapeutic agents.
Structure based design, synthesis and activity studies of small hybrid molecules as HDAC and G9a dual inhibitors.
Lanlan Zang,Shukkoor Muhammed Kondengaden,Qing Zhang,Xiaobo Li,Dilep Kumar Sigalapalli,Shameer M. Kondengadan,Kenneth Huang,Keqin Kathy Li,Shanshan Li,Zhongying Xiao,Liuqing Wen,Hailiang Zhu,Bathini Nagendra Babu,Lijuan Wang,Fengyuan Che,Peng George Wang +15 more
TL;DR: The structure based design, synthesis, and screening for the dual activity of the small molecules led to the discovery of compound 14 which displays promising inhibition of both G9a and HDAC in low micro-molar range in cell based assays.
SAHA-based novel HDAC inhibitor design by core hopping method.
Lan-Lan Zang,Xue-Jiao Wang,Xiaobo Li,Shu-Qing Wang,Wei-Ren Xu,Xian-Bin Xie,Xian-Chao Cheng,Huan Ma,Run-Ling Wang +8 more
TL;DR: This work provided an approach to design novel high-efficiency HDAC inhibitors with better ADMET properties and molecular dynamics simulation of the representative compound 101 was performed to study the stability of HDAC8-inhibitor system.
28
Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition.
Zhen Shu,Zhen Shu,Zhen Li,Huanhuan Huang,Yan Chen,Jun Fan,Li Yu,Zhihui Wu,Ling Tian,Qi Qi,Shuang Peng,Changyong Wei,Zhongqiu Xie,Xiaobo Li,Qi Feng,Hao Sheng,Guangqiang Li,Dongping Wei,Changliang Shan,Changliang Shan,Guo Chen +20 more
TL;DR: It is reported that RRM1 is phosphorylated at Ser 559 by CDK2/cyclin A during S/G2 phase, which enhances RNR enzymatic activity and is required for maintaining sufficient dNTPs during normal DNA replication.
20